Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimetoran Effect on Mycophenolate Mofetil PK in Healthy Men
NCT04039373Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of afimetoran in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration, Area under the concentration-time curve from time zero to the time of the last quantifiable concentration and 1 more. Started Jul 2019; status: completed.
02
Drugs
afimetoran
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT04039373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04039373.